Manning, Elizabeth A <br/><br/>
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jul 2007 
 - 3951-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-07-0374  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--pharmacology<br/>Animals<br/>Antibodies, Monoclonal--therapeutic use<br/>Antigen Presentation<br/>Antineoplastic Agents--pharmacology<br/>CD8-Positive T-Lymphocytes--metabolism<br/>Cancer Vaccines<br/>Cell Line, Tumor<br/>Flow Cytometry<br/>Humans<br/>Immune System<br/>Lymphocytes, Tumor-Infiltrating--metabolism<br/>Mice<br/>Neovascularization, Pathologic<br/>Vascular Endothelial Growth Factor Receptor-2--antagonists & inhibitors